Our mission is to deploy state-of-the-art fusion technology to solve global problems as a scalable path to practical fusion energy. Through our team’s expertise and proprietary technology, we believe we can to achieve this mission. Our guiding philosophy is of long-term, consciously iterative growth, using each achievement as a stepping-stone toward the next phase in the evolution of our technology and our business. To these ends, our leadership is focused on good, sustainable, and forward-thinking corporate governance, running SHINE with transparency, and ethical leadership that prioritizes our core values.

Meet the SHINE executive team

Chief Executive Officer

Read More

President & Chief Strategy Officer

Read More

 Vice President of Global Sales & Europe

Read More

 Vice President,
Regulatory Affairs & Quality

Read More

General Manager, Systems and Manufacturing Division

Read More

Chief Financial Officer

Read More

Vice President of
Special Projects

Read More

General Manager, Therapeutics Division

Read More

Chief Technology Officer

Read More

Vice President of Engineering

Read More

Chief Business Development Officer

Read More

General Counsel & Corporate Secretary

Read More

Chief of Staff & Vice President Government Affairs

Read More

Vice President of Cybersecurity and Information Technology

Read More

Senior Technical Advisor

Read More

Chief Accounting Officer

Read More

Meet our board of directors

Greg Piefer

Mr. Piefer is the founder and CEO of SHINE Medical Technologies and has 13 years of executive management experience at growth stage technology companies. Before SHINE, he served as the President of Phoenix Nuclear Labs, where he managed the development of high-output particle sources. He formerly served as the Chief Technical Officer to Gillware Inc., a leading data recovery and backup company. He holds a Ph.D. in nuclear engineering, and B.S. degrees in physics and electrical and computer engineering from the University of Wisconsin–Madison. Greg has received numerous awards and honors including the prestigious UW-Madison Early Career award, is the primary inventor on multiple patents and author or co-author of numerous publications and serves on the boards of several profit and non-profit entities. His passion is the growth of technology companies that take scientific advancement to commercialization, providing the opportunity to serve and better humanity. 

Todd Asmuth

Mr. Asmuth has been a member of SHINE’s board since 2013 and has 25 years of experience as an operator, investor and board member in early-stage companies. He joined SHINE from AquaMost, Inc., where he served as CEO. Todd became SHINE’s President in September 2015 and served in the additional role of Chief Financial Officer from 2018 to 2021. In 2021, he was appointed Chief Strategy Officer while retaining his responsibilities as SHINE’s President. Prior to his tenure at AquaMost, he was the President of Surebond, Inc., a specialty chemical manufacturer of environmentally friendly adhesives and sealants. He has a history of successfully taking companies from concept to commercialization to profitability using lean startup, customer-focused product development techniques. He sits on the boards of directors of multiple early-stage companies and non-profit organizations. Early in his career, Todd spent four years in management consulting with Booz Allen & Hamilton on strategy engagements with Fortune 500 companies. Todd earned an M.B.A. with honors from the Kellogg School of Management at Northwestern University and a B.S. in mechanical engineering from Yale University. He is a member of the Society of Petroleum Engineers.

Dr. Thomas “Rock” Mackie, Ph.D.

Dr. Mackie is an Emeritus Professor in the Departments of Medical Physics, Human Oncology, and Engineering Physics at the University of Wisconsin–Madison and serves as the Board Chair for the UW Health Isthmus Project. He is the author of more than 180 peer-reviewed publications, 50 patents, and has supervised more than 40 Ph.D. students. With his expertise in radiation therapy treatment planning and intensity-modulated radiotherapy, his group developed the PinnacleTM treatment planning system, now marketed by Philips Medical. He was a co-founder and Chairman of the Board of TomoTherapy, Inc., a Madison-based public company (NASDQ: TOMO) that employed 650 people. Dr. Mackie received his B.S. in Physics from the University of Saskatchewan in 1980 and his Ph.D. in Physics from the University of Alberta in 1984. 

Gregory OD Smith

Mr. Smith has 41 years of leadership experience in the nuclear and power industries. During that time, he established a track record of developing leaders, creating effective partnerships and establishing operational excellence. He serves as a member on several boards as well as an instructor in leadership in the US, Canada and Europe. Gregory served as the Chairman of URENCO UK, URENCO’s Chief Culture Officer as well as Chairman of the Board and Chief Executive Officer for Louisiana Energy Services (LES), a wholly owned U.S. subsidiary of URENCO. As CEO of LES, he oversaw the construction and startup of the National Enrichment Facility in New Mexico. Before joining URENCO/LES, Mr. Smith worked for Ontario Power Generation as the Senior Vice President for the four-unit Darlington Nuclear station. From 1992-2002, he worked at Energy Northwest where he held several positions, including Operations Division Manager, Plant General Manager, Vice President Nuclear Operations, and Vice President, Generation. 

Paul Ryan

Mr. Ryan was the 54th Speaker of the U.S. House of Representatives. He was the youngest speaker in nearly 150 years. During his tenure, Mr. Ryan spearheaded efforts to reform our nation’s tax code, rebuild our national defense, expand domestic energy production, combat the opioid epidemic, reform our criminal justice system, and promote economic opportunity. As Chairman of the House Ways and Means Committee, he worked to protect health care choices, advance free trade and strengthen the economy. Mr. Ryan also served as Chairman of the House Budget Committee. In 2012, he was selected to serve as his party’s vice-presidential nominee. Mr. Ryan was elected to Congress at age 28 and represented Wisconsin’s First District for two decades. He serves on the board of directors of the Fox Corp. He was named a Professor-of-the-Practice at the University of Notre Dame for the 2019-2020 academic year. He holds a degree in economics and political science from Miami University in Ohio and was awarded an honorary doctorate by the university. 

David Newberg

Mr. Newberg began his career in 1980 as a law clerk for a U.S. District Court Judge in the Southern District of New York. He has extensive experience in corporate and commercial matters, intellectual property, real estate development and financing, mergers and acquisitions, including advice and representation in the financing and securities areas, both public and private. Mr. Newberg represents corporations and joint ventures both here and abroad in high technology and basic industry, acquisitions and divestitures and intellectual property matters, including licensing and distribution of high technology products and processes. In addition, Mr. Newberg provides legal services to individuals and family businesses and their estate and succession planning issues. Among his pro bono activities, Mr. Newberg serves on the panel of mediators for the Federal Courts in the Southern District of New York. He has also been an Adjunct Professor of Law at Pace University Law School where he taught Securities Regulation. He earned an A.B. degree from Princeton University and his J.D. degree from Columbia University. 

Tamanna Bembenek, Ph.D.

Dr. Bembenek is a senior health care executive with broad experience in imaging and radiopharmaceuticals. She has more than 20 years of global experience in marketing, sales, product development, strategy and commercialization. She has a strong track record of opening new markets through the entire product cycle. Dr. Bembenek is Senior Vice President, Health Systems Marketing, at Royal Philips. She joined Philips in 2013 as Senior Director Of Global Product Marketing for the company’s magnetic resonance imaging products. She held other global marketing leadership positions before being appointed to her current position. Before joining Philips, Dr. Bembenek spent more than a decade as a Marketing Leader in Diagnostic Imaging at GE Healthcare, including global leadership positions in PET/SPECT and CT imaging for neurological applications, and global point-of-care ultrasound marketing and product management. Dr. Bembenek earned a B.A. from Lake Forest College and a Ph.D. in biochemistry from the Texas A&M Health Science Center. 

Jean Rogers, Ph.D.

Dr. Rogers joined SHINE’s board in March 2021. Dr. Rogers has more than two decades of experience advising companies on environmental, social and governance criteria, and long-term value creation. She is the founder and former Chief Executive Officer of the Sustainability Accounting Standards Board. Under Dr. Rogers’ leadership, the SASB developed sustainability accounting standards for 79 industries and launched education programs in sustainability accounting. Today, SASB is the gold standard for disclosure of material ESG risks, recognized by long-term institutional investors around the world. Dr. Rogers also is an advisor to the Long-Term Stock Exchange, a national stock exchange approved by the U.S. Securities and Exchange Commission in 2019. The exchange supports companies and investors committed to the creation of long-term shareholder value. She earned undergraduate and master’s degrees from Manhattan College, Riverdale, N.Y. She earned a Ph.D. in environmental engineering from the Illinois Institute of Technology and was a post-doctoral fellow at Harvard University. 

Brett Chugg

Mr. Chugg joined SHINE’s Board of Directors in June 2021. He has more than 25 years of experience leading strategic investing in venture capital, mergers and acquisitions, private equity, and growth equity. As Managing Director at Koch Disruptive Technologies (KDT), Brett has led investment initiatives across the software, medical technologies, life sciences, semiconductors, and industrial technology sectors.

Mr. Chugg is a board member at Sense Biodetection, a UK-based diagnostics company; Vayyar Imaging, an Israel-based 4D imaging radar solutions company; and INSIGHTEC, a transformative health care platform applying focused ultrasound. During his 20-plus years at Koch Industries, Brett has served as Managing Director at Koch Equity Development; vice president of INVISTA, a subsidiary of Koch Industries; and Managing Director at Koch Ventures, where he helped develop and lead Koch’s initial venture investment strategy. Brett holds a bachelor’s degree from Weber State University and an MBA in finance and strategy from Brigham Young University.

Meet Our Advisers

Dr. Paul M. DeLuca

Dr. DeLuca joined the faculty of the University of Wisconsin-Madison in 1971.He has served as a Professor in the Departments of Medical Physics, Radiology, Human Oncology, Engineering Physics and Physics. He now serves as Provost and Vice Chancellor for Academic Affairs. Dr. DeLuca’s research interests have concentrated on fast neutron dosimetry, including production of intense sources of fast neutrons, determination of elemental neutron kerma factors and application of microdosimetry to radiation dosimetry. He is Vice Chairman of the International Commission on Radiation Units and Measurements at Los Alamos. Dr. DeLuca received his B.S. in physics and math in 1966 and a Ph.D. in nuclear physics from the University of Notre Dame in 1971.

Brad Wucherpfennig

Mr. Wucherpfenning is president of Baker Construction Enterprises, Inc. Prior to joining Baker in 2010, served as CEO of Phillips-Medisize, a global leader in outsource design, development, and technology-driven manufacturing for drug delivery, medical device, and medical diagnostic products. Mr. Wucherpfennig served as the Executive Vice President and Chief Operating Officer of Schwing America, Inc., a member of the Schwing Group, a worldwide designer, manufacturer and distributor of concrete production and handling equipment. His career began with Ernst & Young in Minnesota, where he performed client audits as a CPA. After his time in public accounting, he served as the Director of International Finance for Synder General Corp., a designer and manufacturer of commercial and industrial air conditioning and handling equipment. Mr. Wucherpfennig has a degree in finance and accounting from the University of Wisconsin-Madison and holds an M.B.A. from the University of Minnesota. He has served on numerous boards in the construction, manufacturing, and medical technology industries. 

Frederick Robertson, M.D.

Dr. Robertson is a seasoned corporate director and health care executive in the medical device, life science, and pharmaceutical industries. He has been a Venture Partner at Baird Capital since 2011 and retired from the anesthesiology faculty at the University of Wisconsin School of Medicine and Public Health in 2018. Previously, Dr. Robertson held the role of CEO and Director of TomoTherapy Inc. before that company was acquired in 2011. Prior to joining TomoTherapy, Dr. Robertson served in a variety of roles in the medical industry, including President and CEO of GE Marquette Medical Systems and later as CEO of GE Medical Systems, as well as management positions with Marquette Medical Systems, including President and CEO. He served as a Director of Lantheus Holdings from 2016-2021. He serves on the board of directors of the University of Wisconsin Foundation, the Morgridge Institute for Research, Alpha Source, Inc., Ensodata, Inc., Elucent, Inc, and Zurex Pharma, Inc. Dr. Robertson received his M.B.A. from San Diego State University and earned his M.D. from University of Wisconsin Medical School. 

Harrison Schmitt, Ph.D.

Dr. Harrison Schmitt has a diverse professional background having served as a geologist, pilot, astronaut, businessman, writer and U.S. Senator. Selected for the Scientist-Astronaut Program in 1965, he served as a Mission Scientist in support of the Apollo 11 mission. After training as back-up lunar module pilot for Apollo 15, Dr. Schmitt flew in space as lunar module pilot for Apollo 17, the last Apollo mission to the Moon. He was the only scientist and the last of 12 men to step onto the Moon. He served in the U.S. Senate, continues to work in science, aerospace and business, and chaired the NASA Advisory Council from 2005-2008. Schmitt serves as Adjunct Professor of engineering at the University of Wisconsin-Madison. In addition to being active in considerations of space biomedical adaptation, he has worked in the biomedical field as acting CEO for the Lovelace Medical Foundation and is a Director of PHDx Systems, a software developer and supplier for medical device outcomes. Schmitt is the author of “Return to the Moon” (Copernicus-Praxis 2006), a book advocating a private sector initiative to develop lunar helium-3 fusion power for use on Earth. 

James Connaughton

Mr. Connaughton is Executive Vice President of C3 Energy, which offers big data energy analytics solutions to utilities and to oil and gas companies. Prior to joining C3 Energy, Mr. Connaughton served as Executive Vice President and Senior Policy Advisor of Exelon Corp., and Executive Vice President, Corporate Affairs, Public and Environmental Policy for Constellation Energy. From 2001 to 2009, Mr. Connaughton was Chairman of the White House Council on Environmental Quality. In this capacity, he served on President Bush’s staff as Senior Environment, Energy and Natural Resources Advisor and as Director of the White House Office of Environmental Policy. He holds a bachelor’s degree from Yale University and a J.D. from Northwestern University School of Law. 

Scott Klug

Mr. Klug is the Managing Director of Public Affairs at the national law firm of Foley & Lardner LLP. He chairs the firm’s client service team. For eight years, Mr. Klug represented Madison, Wisconsin, in the U.S. House of Representatives, where he developed an expertise in health care, energy policy and financial services. He was appointed by President Bush for two terms to the Advisory Committee to the United States Trade Representative. Prior to his election to Congress, he was an Emmy award-winning reporter and anchor in Washington, D.C., Seattle and his native Wisconsin. Mr. Klug is a novelist whose freelance writing has appeared in a number of U.S. newspapers and magazines. Before he joined Foley, he founded a regional magazine and book publishing company, which he sold in 2007. Mr. Klug holds an M.B.A. in finance from the University of Wisconsin, a master’s degree in journalism from Northwestern and a B.A. from Lawrence University. 

Christopher Manuele

Mr. Manuele is a results-oriented, innovative executive with 35 years of comprehensive U.S. and international expertise in nuclear medicine and medical isotope production. A long-time veteran of Amersham Health and GE Healthcare, he has launched core products, expanded products internationally, led the design, construction and FDA-approval of two brand new U.S. manufacturing facilities, and held responsibility for several full-GMP radiopharmaceutical manufacturing sites across the United States and Europe. Before his retirement in 2008, Mr. Manuele served as General Manager of Global Nuclear Medicine Supply Chain for GE Healthcare, and General Manager of Oncura, GE’s global I-125 brachytherapy seeds business. He has an impeccable track record of operational excellence, continuous profitability improvement, and implementation of industry-leading quality systems. 

Donald J. Whelley

Mr. Whelley is the Managing Member of DJW Advisors, providing advisory services to institutional and high net worth clients. He has worked for more than 30 years in energy and financial services providing valuation and advisory services and most recently supporting clients investing in other industry sectors including mining and biotech. After graduating with a B.S. in accounting from Clarkson University, Mr. Whelley began his professional career as an auditor for Arthur Andersen. His career has included accounting, finance and acquisition work for companies involved in oil and gas, agricultural biotech, broker dealer and syndication of real estate investments and energy consulting. In addition to being a advisor of SHINE, Mr. Whelley also serves as a Director of Phoenix Nuclear Labs, a private manufacturer of commercial neutron generators; a Director of GeoResources Inc., a Houston, Texas-based publicly traded exploration & production company; Board Observer of Dynamis Therapeutics, Inc., a private biotech company, Board Observer of Flugen, Inc., a private manufacturer of medical devices and vaccines, and Advisory Board Member of Blue Ocean Consulting, Inc., an internet software and consulting firm.

Gordon Gunnlaugsson 

Mr. Gunnlaugsson was employed at Marshall and Ilsley Corporation, an S&P 500 banking company, for 3 years, serving most recently as Chief Financial Officer, Executive Vice President and then as a Director. He is a Principal in Lakeview Equity Partners, a private equity firm in Milwaukee, Wisconsin. He also serves as Chairman of the UW School of Business Puelicher Center for Banking and as Director of Lease Crunch, LLC. In the past, Mr. Gunnlaugsson also served as director for a variety of firms including SHINE Medical Technologies, West Bend Mutual Insurance Company, Fiduciary Management Mutual Funds, and Renaissance Learning, Inc. He has also served as Chairman of the Milwaukee Economic Development Corporation, Chairman of the Medical College of Wisconsin Cardiovascular Center Advisory Board, and Chairman of the UW School of Business Dean’s Advisory Board. He is a C.P.A. and holds a B.B.A. and M.B.A. from the UW School of Business and is a recipient of their Distinguished Alumni Award.